RAPT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.839

-91.4%

-0.657

+2.73%

-0.730

+12.31%

Estimates Revision

The market is revising No Change the revenue expectations for RAPT Therapeutics, Inc. (RAPT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 8.05%.

EPS Estimates for FY2025

Revise Upward

+5.86%

In Past 3 Month

Stock Price

Go Up

+8.05%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast RAPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPT is 64.38 USD with a low forecast of 56.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

56.00

Averages

64.38

High

72.00

Current: 0.000

Low

56.00

Averages

64.38

High

72.00

Piper Sandler

Strong Buy

initiated

$95

2026-01-09

New

Reason

Piper Sandler

Price Target

$95

2026-01-09

New

initiated

Strong Buy

Reason

Piper Sandler initiated coverage of Rapt Therapeutics with an Overweight rating and $95 price target. The firm is bullish on the company's lead-asset, ozureprubart, saying the drug is clinically and commercially de-risked by Xolair. It sees Rapt trading up into the data catalyst in the first half of 2027.

TD Cowen

initiated

2025-12-18

Reason

TD Cowen

Price Target

2025-12-18

initiated

Reason

TD Cowen initiated coverage of Rapt Therapeutics with a Buy rating. Rapt Therapeutics' ozureprubart, an improved IgE monoclonal antibody versus Xolair for food allergy and Chronic Spontaneous Urticaria, offers less frequent dosing and broader efficacy, with Chinese Phase 2 CSU data showing comparable or better efficacy and 16-week durability, the analyst tells investors in a research note. Ongoing Phase 2b food allergy data are expected in the first half of 2027, supporting a potential global Phase 3 start by year-end 2026 and highlighting multi-blockbuster potential, TD Cowen says.

H.C. Wainwright

Douglas Tsao

NULL -> Buy

maintain

$34 -> $40

2025-12-09

Reason

H.C. Wainwright

Douglas Tsao

Price Target

$34 -> $40

2025-12-09

maintain

NULL -> Buy

Reason

H.C. Wainwright analyst Douglas Tsao raised the firm's price target on Rapport Therapeutics to $40 from $34 and keeps a Buy rating on the shares. The firm says the new data support RAP-219's potential to become a "major player in the fast-expanding" focal onset seizures market. RAP-219 showed "rapid and deep" anti-seizure effect across disease severities in refractory focal epilepsy patients in the Phase 2 data, the analyst tells investors in a research note.

JPMorgan

NULL -> Overweight

maintain

$55 -> $57

2025-11-12

Reason

JPMorgan

Price Target

$55 -> $57

2025-11-12

maintain

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on Rapt Therapeutics to $57 from $55 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology group.

Barclays

Overweight

downgrade

$58 -> $56

2025-11-07

Reason

Barclays

Price Target

$58 -> $56

2025-11-07

downgrade

Overweight

Reason

Barclays lowered the firm's price target on Rapt Therapeutics to $56 from $58 and keeps an Overweight rating on the shares following the Q3 report.

Clear Street

Buy

maintain

$60

2025-11-06

Reason

Clear Street

Price Target

$60

2025-11-06

maintain

Buy

Reason

Clear Street views the shares of Rapt Therapeutics as "exceptionally compelling" following the company's Q3 report. The company achieved a "major milestone with compelling" Phase 2 chronic spontaneous urticaria data from its Chinese partner, Shanghai Jeyou Pharmaceutical, the analyst tells investors in a research note. The firm believes ozureprubart "stands out" with quarterly dosing, which is triple the convenience compared to Xolair's monthly regimen. Clear says Rapt shares are little changed spite this "significant de-risking event" and its financing overhang being eliminated. The firm keeps a Buy rating on shares with a $60 price target.

Valuation Metrics

The current forward P/E ratio for RAPT Therapeutics Inc (RAPT.O) is -10.65, compared to its 5-year average forward P/E of -6.10. For a more detailed relative valuation and DCF analysis to assess RAPT Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.10

Current PE

-10.65

Overvalued PE

-2.76

Undervalued PE

-9.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.75

Current EV/EBITDA

-6.74

Overvalued EV/EBITDA

-0.43

Undervalued EV/EBITDA

-7.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

415.52

Current PS

0.00

Overvalued PS

1465.79

Undervalued PS

-634.76

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 392% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

RAPT News & Events

Events Timeline

No data

News

9.0

01-08NASDAQ.COM

Rapport Therapeutics (RAPP) Receives FDA Clearance to Advance RAP-219 into Phase 3 Trials

6.5

2025-11-14Yahoo Finance

Recent Developments Influencing the Randoncorp Investment Narrative

6.0

2025-11-07Benzinga

Barclays Keeps Overweight Rating on RAPT Therapeutics, Reduces Price Target to $56

People Also Watch

Frequently Asked Questions

What is RAPT Therapeutics Inc (RAPT) stock price today?

The current price of RAPT is 32.43 USD — it has increased 3.94 % in the last trading day.

What is RAPT Therapeutics Inc (RAPT)'s business?

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.

What is the price predicton of RAPT Stock?

What is RAPT Therapeutics Inc (RAPT)'s revenue for the last quarter?

RAPT Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is RAPT Therapeutics Inc (RAPT)'s earnings per share (EPS) for the last quarter?

RAPT Therapeutics Inc. EPS for the last quarter amounts to -0.65 USD, decreased -82.85 % YoY.

What changes have occurred in the market's expectations for RAPT Therapeutics Inc (RAPT)'s fundamentals?

How many employees does RAPT Therapeutics Inc (RAPT). have?

RAPT Therapeutics Inc (RAPT) has 68 emplpoyees as of January 09 2026.

What is RAPT Therapeutics Inc (RAPT) market cap?

Today RAPT has the market capitalization of 864.58M USD.